IntelGenx to Promote VetaFilm™ Oral Film Technology at Human Biotech & Animal Health Business Partnering Summit

IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it will promote its proprietary VetaFilm™ oral film technology for companion animal drug delivery at the Human Biotech & Animal Health Business Partnering Summit taking place on April 9, 2019 in Boston, MA.

VetaFilm™ is a rapidly disintegrating oral film designed to improve drug performance, promote compliance and increase the ease of drug administration in companion animals. As small as a postage stamp, the film can be flavoured to appeal to companion animals for spontaneous intake and will adhere on contact in the mouth.  Moreover, VetaFilm™ buccal absorption has the potential for improved drug efficacy, faster onset of action and reduced side effects by avoiding first-pass metabolism.

VetaFilm™ technology is compatible with a wide variety of actives such as cannabinoids. According to primary research conducted by IntelGenx’s team, cannabinoid-containing VetaFilm™ animal health products are in high demand by pet owners. Recent studies have shown that cannabidiol significantly reduces pain and improves mobility in dogs with osteoarthritis1.

“We are excited to be a part of the Human Biotech & Animal Health Business Partnering Summit,” said Horst G. Zerbe, President and CEO of IntelGenx. “The Summit is an excellent forum to demonstrate the innovative possibilities with VetaFilm™ and how this oral film technology can serve unmet medical needs in veterinary health.”

Reference 1 Gamble L et al., “Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs”, Front. Vet. Sci., 23 July 2018.

About IntelGenx Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ and VetaFilmTM technology platforms.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, which was established for oral film technology platforms, offers by supporting lab-scale to pilot- and commercial-scale production. More information about the company can be found at www.intelgenx.com. Forward Looking Statements  This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements. Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For IntelGenx:
 
Stephen Kilmer
Investor Relations
[phone] ext 232
[e-mail]
 
Or
 
Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
[phone] ext 203
[e-mail]